Arnout Ploos van Amstel
Direktor/Vorstandsmitglied bei ZURA BIO LIMITED
Vermögen: 362 000 $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Arnout Ploos van Amstel
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 18 | |
| Public Company | Pharmaceuticals: Major | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Arnout Ploos van Amstel
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Comptroller/Controller/Auditor Corporate Officer/Principal Director/Board Member | |
| INCYTE CORPORATION | Pharmaceuticals: Major | Corporate Officer/Principal | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Corporate Officer/Principal | |
| REGENERON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
D.E. Shaw & Co., Inc.
 D.E. Shaw & Co., Inc. Investment ManagersFinance D.E. Shaw & Co., Inc. engages in the provision of investment advisory services. The firm offers services to pooled investment vehicles. The company was founded by David E. Shaw in 1988 and was headquartered in New York, NY. | Investment Managers | Corporate Officer/Principal | |
Impax Laboratories LLC
 Impax Laboratories LLC Pharmaceuticals: MajorHealth Technology Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Compliance Officer | |
| ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer Director/Board Member Director/Board Member Corporate Officer/Principal Human Resources Officer Compliance Officer | |
| SYNTARA LIMITED | Pharmaceuticals: Major | Director/Board Member | |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Kaleo, Inc.
 Kaleo, Inc. Pharmaceuticals: MajorHealth Technology Kaleo, Inc. develops drug/device combination products. Its products empower patients to gain freedom from their medical condition. The firm's capabilities include drug development, device development, regulatory and clinical, manufacturing, commercialization and data generation. The company was founded by Eric S. Edwards and Evan T. Edwards in 2005 and is headquartered in Richmond, VA. | Pharmaceuticals: Major | Compliance Officer | |
| XTL BIOPHARMACEUTICALS LTD. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
| University of Adelaide | College/University | Doctorate Degree | |
| University of Oxford | College/University | Graduate Degree Doctorate Degree | |
| University of Cambridge | College/University | Undergraduate Degree | |
| Sweet Briar College | College/University | Undergraduate Degree | |
| University of Messiah | College/University | Undergraduate Degree | |
| State University of New York at Albany | College/University | Undergraduate Degree | |
| University of California, Riverside | College/University | Undergraduate Degree | |
| University of Bristol | College/University | Undergraduate Degree | |
| University of Leicester | College/University | Undergraduate Degree | |
Daiichi Sankyo, Inc.
 Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Pharmaceuticals: Major | Sales & Marketing | |
InCarda Therapeutics, Inc.
 InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Biotechnology | Chief Executive Officer | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Immune Tolerance Network
 Immune Tolerance Network Miscellaneous Commercial ServicesCommercial Services Immune Tolerance Network provides clinical research services. It offers immune tolerance therapies for autoimmune disease, allergies and asthma, organ transplantation, and type 1 diabetes. The company was founded by Jeffrey A. Bluestone in 1999 and is headquartered in Seattle, WA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Johns Hopkins Bloomberg School of Public Health | College/University | Corporate Officer/Principal | |
| Harvard College | College/University | Undergraduate Degree Undergraduate Degree | |
| Pepperdine University School of Law | College/University | Graduate Degree | |
Tiziana Life Sciences Ltd. (United Kingdom)
 Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| PULMATRIX, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| West Virginia University School of Medicine | College/University | Doctorate Degree | |
EUSA Pharma (UK) Ltd.
 EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom. | Medical Distributors | Chief Tech/Sci/R&D Officer | |
| EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Oxford University Medical School | College/University | Undergraduate Degree | |
Izana Bioscience Ltd.
 Izana Bioscience Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Izana Bioscience Ltd. is a British biotech company. The company is based in London, UK. The company's website, izanabio.com, provides general information about the company. The company was founded in 2017 by Someit Sidhu. Someit Sidhu has been the CEO since 2017. | Biotechnology | Chief Executive Officer | |
| DERMTECH, INC. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Pathios Therapeutics Ltd.
 Pathios Therapeutics Ltd. BiotechnologyHealth Technology Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Founder | |
Moonlake Immunotherapeutics AG
 Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| JATT Ventures LP | Chief Executive Officer | ||
| Akaza Bioscience Ltd. | Chief Executive Officer | ||
| Zenios Bioscience LLP | Chief Executive Officer | ||
| Moonlake Immunotherapeutics Ltd. | Chief Tech/Sci/R&D Officer | ||
Adiso Therapeutics, Inc.
 Adiso Therapeutics, Inc. BiotechnologyHealth Technology Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
| CADRENAL THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Miscellaneous Commercial Services | Founder Director/Board Member |
Statistik
International
| Vereinigte Staaten | 27 |
| Vereinigtes Königreich | 14 |
| Australien | 3 |
| Cayman Islands | 3 |
| Deutschland | 2 |
Sektoral
| Health Technology | 25 |
| Consumer Services | 15 |
| Finance | 3 |
| Commercial Services | 3 |
| Distribution Services | 2 |
Operativ
| Director/Board Member | 50 |
| Corporate Officer/Principal | 38 |
| Chief Executive Officer | 21 |
| Independent Dir/Board Member | 20 |
| Chief Tech/Sci/R&D Officer | 18 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Amit Munshi | 27 |
| Jennifer Jarrett | 18 |
| Christopher Cabell | 16 |
| Neil Graham | 14 |
| Steven Schoch | 11 |
| Sandeep Kulkarni | 11 |
| Michael Howell | 10 |
| Theresa Lowry | 9 |
| Robert Lisicki | 9 |
| Someit Sidhu | 8 |
| Parvinder Singh Thiara | 7 |
| Kimberly Ann Davis | 7 |
| Verender Badial | 6 |
| Gary Whale | 5 |
| Oliver Daltrop | 5 |
- Börse
- Insiders
- Arnout Ploos van Amstel
- Unternehmensverbindungen